publication date: Feb. 3, 2014


Kidney Cancer

Patients on Hypertension Medications Lived Longer, Analysis Shows

Patients with advanced kidney cancer lived an average of seven months longer if they were taking a common type of high blood pressure medication during treatment, according to an analysis of clinical trials data.

Patients on angiotensin system inhibitors, including angiotensin-converting-enzyme inhibitor and angiotensin system blockers, survived an average of 26.68 months compared with 17.05 months in those who did not receive the drugs.

The study results will be presented Feb. 1 at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco.

The greatest survival benefits were seen in patients who were taking ASIs while being treated with drugs that targeted the vascular endothelial growth factor pathway, according to the study.

Researchers used a database of results of phase II and III clinical trials sponsored by Pfizer Inc. The pooled data included 4,736 patients treated between 2003 and 2013 for metastatic kidney cancer. The patients were generally males, younger than 65, whose disease was considered intermediate-risk.

The majority were treated with the targeted anti-VEGF agents sunitinib, sorafenib, and axitinib. Others received temsirolimus, which inhibits the mTOR protein, and interferon, which stimulates the immune system to fight tumors. Survival gains were greatest in patients who took ASIs while in treatment with anti-VEGF drugs, compared with mTOR inhibitors or interferon, the analysis revealed.

“Though larger prospective studies are needed to further investigate this hypothesis, based on the results of this study, an ASI should be considered for patients with metastatic renal cell carcinoma who need an antihypertensive and do not have any contraindications that preclude their use, especially in patients receiving … Continue reading CCL Jan – Kidney Cancer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.